Jackson Mittlesteadt

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Prostate Cancer

Gene Expression

Top Venues

Science immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Yini Zhu, Yun Zhao, Jiling Wen, Sheng Liu, Tianhe Huang, Ishita Hatial, Xiaoxia Peng, Hawraa Al Janabi, Gang Huang, Jackson Mittlesteadt, Michael Cheng, Atul Bhardwaj, Brandon L Ashfeld, Kenneth R Kao, Dean Y Maeda, Xing Dai, Olaf G Wiest, Brian S J Blagg, Xuemin Lu, Liang Cheng, Jun Wan, Xin Lu
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Science immunology 8 (81) (2023)
Yini Zhu, Yun Zhao, Jiling Wen, Sheng Liu, Tianhe Huang, Ishita Hatial, Xiaoxia Peng, Hawraa Al Janabi, Gang Huang, Jackson Mittlesteadt, Michael Cheng, Atul Bhardwaj, Brandon L Ashfeld, Kenneth R Kao, Dean Y Maeda, Xing Dai, Olaf G Wiest, Brian S J Blagg, Xuemin Lu, Liang Cheng, Jun Wan, Xin Lu
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Science immunology 8 (81) (2023)
Yini Zhu, Yun Zhao, Jiling Wen, Sheng Liu, Tianhe Huang, Ishita Hatial, Xiaoxia Peng, Hawraa Al Janabi, Gang Huang, Jackson Mittlesteadt, Michael Cheng, Atul Bhardwaj, Brandon L Ashfeld, Kenneth R Kao, Dean Y Maeda, Xing Dai, Olaf G Wiest, Brian S J Blagg, Xuemin Lu, Liang Cheng, Jun Wan, Xin Lu
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Science immunology 8 (81) (2023)
Yini Zhu, Yun Zhao, Jiling Wen, Sheng Liu, Tianhe Huang, Ishita Hatial, Xiaoxia Peng, Hawraa Al Janabi, Gang Huang, Jackson Mittlesteadt, Michael Cheng, Atul Bhardwaj, Brandon L Ashfeld, Kenneth R Kao, Dean Y Maeda, Xing Dai, Olaf G Wiest, Brian S J Blagg, Xuemin Lu, Liang Cheng, Jun Wan, Xin Lu
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Science immunology 8 (81) (2023)